# Kardigan Inc. (KARD)

Source: https://www.quantisnow.com/company/KARD
Generated: 2026-11-14T00:48:52.715Z

- Ticker: KARD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0002123613
- Website: https://www.kardigan.bio/

## About

Kardigan is a clinical-stage precision cardiovascular company developing medicines that target the root cause of diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies.

## Latest KARD news and filings

- 2026-11-12 12:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kardigan Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kardigan-inc-6786146)
- 2026-11-12 12:02 UTC [SEC Form 8-K] [Kardigan Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kardigan-inc-filed-sec-form-8-k-results-of-operations-and-6786096)
- 2026-11-12 12:00 UTC [Earnings] [Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates](https://www.quantisnow.com/insight/kardigan-reports-third-quarter-2026-financial-results-and-recent-business-6786012)
- 2026-11-11 12:00 UTC [Conference Announcement] [Kardigan to Participate in the Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/kardigan-to-participate-in-the-jefferies-global-healthcare-conference-6785138)
- 2026-11-06 21:06 UTC [SEC Form 8-K] [Kardigan Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kardigan-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6778920)
- 2026-11-06 21:05 UTC [Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis](https://www.quantisnow.com/insight/kardigan-completes-enrollment-in-phase-2b-katalyst-av-trial-and-announces-6778825)
- 2026-11-04 11:24 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on Kardigan with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-kardigan-with-a-new-price-6771029)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KARD
- Earnings history: https://www.quantisnow.com/earnings/KARD
- Dividend history: https://www.quantisnow.com/dividends/KARD
- Insider transactions: https://www.quantisnow.com/insiders/KARD
- Options chain: https://www.quantisnow.com/options/KARD
- SEC 8-K filings only: https://www.quantisnow.com/company/KARD/8-k
- RSS and alerts for KARD: https://www.quantisnow.com/docs/rss-feeds.md